Sector: Health Care
Deal type: Management buyout
Investment date: April 2010
Realisation date: November 2014
In IPS – now IPS Pharma – we saw a tremendous opportunity to take a business with exceptional entrepreneurial spirit and turn it into a national leader in the supply of bespoke medicines.
We bought a majority stake in Surrey-based Vertical Pharma Resources, which traded as Integrated Pharmaceutical Services (IPS), in April 2010.
“The Elysian team had an in-depth understanding of our sector, which allowed them to understand the requirements of the management team. They worked closely with us to help develop a clear strategic vision for the business, to secure the growth of the company and create value. I liked their professional, can do and supportive approach.”
Operations director, IPS Specials
We were introduced to IPS through our Yorkshire office. The company, founded in 2001 by Ashok Patel, had grown into one of the UK’s leading suppliers of medicines known as ‘specials’ – standard drug compounds adapted to meet the needs of individual patients.
It had demonstrated excellent quality and service with a loyal customer base of independent pharmacies within the M25.
We saw an opportunity to roll out the business, which had a low cost manufacturing base, through building a sales and marketing function. We also brought experience to support Ashok in implementing the systems, processes and infrastructure needed to take the company to the next level.
The specials market underwent significant change with the introduction of a new pricing tariff by UK government department The Department of Health and Social Care in November 2011.
This reduced the value of the market by about 30%, although the increased transparency in the market would benefit quality suppliers such as IPS in the long term.
This was a challenging environment for all specials companies but we supported the management and continued to invest in long-term projects.
Together, we transformed IPS into a national player with a scalable platform, increasing the number of employees from 19 to 54 at the time of exit.
Under our ownership, IPS: